Parabilis Medicines Files for IPO After $2.3B Deal with Regeneron
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Should l Buy REGN?
Source: seekingalpha
- Research Collaboration: Parabilis Medicines has entered into a research agreement with Regeneron valued at up to $2.3 billion, which includes $125 million upfront and potential milestone payments, indicating strong market confidence in the Helicons treatment class.
- IPO Filing Submitted: The company has filed an S-1 with the SEC, aiming to list on Nasdaq under the ticker PBLS, marking a significant step in its financing and market expansion strategy.
- Clear Use of Proceeds: Parabilis disclosed that net proceeds from the IPO will be used to advance its lead product candidate, zolucatetide, which is expected to enter a global registrational Phase 3 trial in H1 2027 targeting patients with rare soft tissue tumors.
- Broad Market Prospects: By collaborating with Regeneron, Parabilis not only secures funding but also leverages Regeneron's VelocImmune technology, enhancing its competitive position in the biopharmaceutical sector and driving long-term growth for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 630.300
Low
637.00
Averages
808.50
High
1057
Current: 630.300
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Parabilis Medicines Files for IPO After $2.3B Deal with Regeneron
- Research Collaboration: Parabilis Medicines has entered into a research agreement with Regeneron valued at up to $2.3 billion, which includes $125 million upfront and potential milestone payments, indicating strong market confidence in the Helicons treatment class.
- IPO Filing Submitted: The company has filed an S-1 with the SEC, aiming to list on Nasdaq under the ticker PBLS, marking a significant step in its financing and market expansion strategy.
- Clear Use of Proceeds: Parabilis disclosed that net proceeds from the IPO will be used to advance its lead product candidate, zolucatetide, which is expected to enter a global registrational Phase 3 trial in H1 2027 targeting patients with rare soft tissue tumors.
- Broad Market Prospects: By collaborating with Regeneron, Parabilis not only secures funding but also leverages Regeneron's VelocImmune technology, enhancing its competitive position in the biopharmaceutical sector and driving long-term growth for the company.
See More
ETF Analysis: FDG Implies 19.53% Upside Potential
- FDG ETF Potential: The American Century Focused Dynamic Growth ETF (FDG) has an implied analyst target price of $161.52 per unit, while trading at $135.13, indicating a 19.53% upside potential, reflecting market optimism about the ETF's future performance.
- Regeneron Upside: Regeneron Pharmaceuticals (REGN) trades at $630.30, with an analyst target price of $876.53, suggesting a potential upside of 39.07%, showcasing strong analyst confidence in its future performance.
- Robinhood Market Expectations: Robinhood Markets (HOOD) is currently priced at $74.16, with an analyst target of $99.86, indicating a 34.66% upside potential, reflecting optimistic market expectations regarding its business growth.
- MPWR Target Analysis: Monolithic Power Systems (MPWR) trades at $1468.11, with an analyst target of $1820.00, suggesting a potential upside of 23.97%, which may attract investor interest in its future growth potential.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $119.78 per share, with a high of $179.64, and a current trading price of $163.87, indicating relative stability in a volatile market that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable technical insights for investors, aiding in better market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETF.
See More
Regeneron Shares Plummet After Phase 3 Trial Fails to Meet Endpoint
- Trial Outcome: Regeneron's Phase 3 melanoma trial of Fianlimab plus Libtayo failed to meet its primary endpoint, resulting in a more than 10% drop in stock price when the market opened on May 18, 2026, indicating significant disappointment among investors.
- Investor Confidence Impact: Despite management's optimistic outlook in March 2026, which suggested a median progression-free survival in the low to mid-teens, the failure to achieve expected results has severely undermined investor confidence and trust in the company's projections.
- Legal Investigation Initiated: Following the trial failure, Regeneron is now facing a legal investigation from investors, who are encouraged to submit their information to explore their legal rights, highlighting concerns over the company's transparency and disclosure practices.
- Market Reaction Analysis: The sharp decline in stock price not only reflects worries about Regeneron's future prospects but may also impact its competitive position in the biopharmaceutical sector, particularly in its rivalry with Merck's Keytruda.
See More
Mixed US Stock Close as Oil Prices Volatile Amid Geopolitical Tensions
- Mixed Market Performance: The S&P 500 index fell by 0.07%, while the Dow Jones Industrial Average rose by 0.32%, and the Nasdaq 100 index decreased by 0.45%, indicating a divergence in market performance amid oil price volatility and geopolitical tensions.
- Oil Price Volatility: Crude oil prices surged to a three-week high on Monday due to Iran's comments on US demands being 'excessive and unrealistic', but prices fell sharply later when President Trump canceled a planned strike on Iran, highlighting the direct impact of geopolitical events on the market.
- Supportive Economic Data: The May NAHB housing market index rose by 3 to 37, exceeding expectations, which indicates resilience in the housing market and may provide some support for stocks.
- Weak Chinese Economic Indicators: China's April industrial production rose by 4.1% year-on-year, below the expected 6.0%, with retail sales and new home prices also underperforming, reflecting potential risks to global growth prospects.
See More
Regeneron Stock Plummets Over 10% After Trial Failure
- Trial Results Disappoint: Regeneron's Phase 3 melanoma trial of fianlimab plus Libtayo failed to meet its primary endpoint, causing the stock to open down over 10% on May 16, 2026, significantly impacting investor confidence and market perception.
- Executives' Optimism: Despite the trial failure, Regeneron executives expressed optimism during healthcare conferences in November and December 2025, suggesting that delays in the LAG-3 study indicated good performance of test arms, reflecting management's confidence in future prospects.
- Investor Legal Rights: Following the sharp stock decline, Regeneron shareholders are encouraged to submit their information to discuss their legal rights, highlighting concerns over the company's transparency and information disclosure practices in the market.
- Potential Misleading Statements Investigation: The investigation focuses on whether Regeneron made materially false or misleading statements regarding the potential and progress of its Phase 3 melanoma trial, aiming to protect investors' interests and pursue potential compensation for losses.
See More
Parabilis Medicines Files for IPO After $2.3B Deal with Regeneron
- Research Collaboration: Parabilis Medicines has entered into a research agreement with Regeneron valued at up to $2.3 billion, which includes $125 million upfront and potential milestone payments, indicating strong market confidence in the Helicons treatment class.
- IPO Filing Submitted: The company has filed an S-1 with the SEC, aiming to list on Nasdaq under the ticker PBLS, marking a significant step in its financing and market expansion strategy.
- Clear Use of Proceeds: Parabilis disclosed that net proceeds from the IPO will be used to advance its lead product candidate, zolucatetide, which is expected to enter a global registrational Phase 3 trial in H1 2027 targeting patients with rare soft tissue tumors.
- Broad Market Prospects: By collaborating with Regeneron, Parabilis not only secures funding but also leverages Regeneron's VelocImmune technology, enhancing its competitive position in the biopharmaceutical sector and driving long-term growth for the company.
See More
ETF Analysis: FDG Implies 19.53% Upside Potential
- FDG ETF Potential: The American Century Focused Dynamic Growth ETF (FDG) has an implied analyst target price of $161.52 per unit, while trading at $135.13, indicating a 19.53% upside potential, reflecting market optimism about the ETF's future performance.
- Regeneron Upside: Regeneron Pharmaceuticals (REGN) trades at $630.30, with an analyst target price of $876.53, suggesting a potential upside of 39.07%, showcasing strong analyst confidence in its future performance.
- Robinhood Market Expectations: Robinhood Markets (HOOD) is currently priced at $74.16, with an analyst target of $99.86, indicating a 34.66% upside potential, reflecting optimistic market expectations regarding its business growth.
- MPWR Target Analysis: Monolithic Power Systems (MPWR) trades at $1468.11, with an analyst target of $1820.00, suggesting a potential upside of 23.97%, which may attract investor interest in its future growth potential.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $119.78 per share, with a high of $179.64, and a current trading price of $163.87, indicating relative stability in a volatile market that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable technical insights for investors, aiding in better market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as these liquidity shifts can affect the performance of individual stocks held within the ETF.
See More
Regeneron Shares Plummet After Phase 3 Trial Fails to Meet Endpoint
- Trial Outcome: Regeneron's Phase 3 melanoma trial of Fianlimab plus Libtayo failed to meet its primary endpoint, resulting in a more than 10% drop in stock price when the market opened on May 18, 2026, indicating significant disappointment among investors.
- Investor Confidence Impact: Despite management's optimistic outlook in March 2026, which suggested a median progression-free survival in the low to mid-teens, the failure to achieve expected results has severely undermined investor confidence and trust in the company's projections.
- Legal Investigation Initiated: Following the trial failure, Regeneron is now facing a legal investigation from investors, who are encouraged to submit their information to explore their legal rights, highlighting concerns over the company's transparency and disclosure practices.
- Market Reaction Analysis: The sharp decline in stock price not only reflects worries about Regeneron's future prospects but may also impact its competitive position in the biopharmaceutical sector, particularly in its rivalry with Merck's Keytruda.
See More
Mixed US Stock Close as Oil Prices Volatile Amid Geopolitical Tensions
- Mixed Market Performance: The S&P 500 index fell by 0.07%, while the Dow Jones Industrial Average rose by 0.32%, and the Nasdaq 100 index decreased by 0.45%, indicating a divergence in market performance amid oil price volatility and geopolitical tensions.
- Oil Price Volatility: Crude oil prices surged to a three-week high on Monday due to Iran's comments on US demands being 'excessive and unrealistic', but prices fell sharply later when President Trump canceled a planned strike on Iran, highlighting the direct impact of geopolitical events on the market.
- Supportive Economic Data: The May NAHB housing market index rose by 3 to 37, exceeding expectations, which indicates resilience in the housing market and may provide some support for stocks.
- Weak Chinese Economic Indicators: China's April industrial production rose by 4.1% year-on-year, below the expected 6.0%, with retail sales and new home prices also underperforming, reflecting potential risks to global growth prospects.
See More
Regeneron Stock Plummets Over 10% After Trial Failure
- Trial Results Disappoint: Regeneron's Phase 3 melanoma trial of fianlimab plus Libtayo failed to meet its primary endpoint, causing the stock to open down over 10% on May 16, 2026, significantly impacting investor confidence and market perception.
- Executives' Optimism: Despite the trial failure, Regeneron executives expressed optimism during healthcare conferences in November and December 2025, suggesting that delays in the LAG-3 study indicated good performance of test arms, reflecting management's confidence in future prospects.
- Investor Legal Rights: Following the sharp stock decline, Regeneron shareholders are encouraged to submit their information to discuss their legal rights, highlighting concerns over the company's transparency and information disclosure practices in the market.
- Potential Misleading Statements Investigation: The investigation focuses on whether Regeneron made materially false or misleading statements regarding the potential and progress of its Phase 3 melanoma trial, aiming to protect investors' interests and pursue potential compensation for losses.
See More
